Jason P. Rhodes - Apr 1, 2022 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Role: Director
Signature: /s/ Jean Franchi, attorney-in-fact
Stock symbol: REPL
Transactions as of: Apr 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 4/5/2022, 04:13 PM
Previous filing: Oct 6, 2021
Next filing: Jun 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REPL	Stock Option (right to buy)	Award	$0	+16.5K		$0.00	16.5K	Apr 1, 2022	Common Stock	16.5K	$18.26	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on April 1, 2022 with respect to 16,500 shares of the Issuer's common stock and vests in full on April 1, 2023.
F2	This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Content

This option was granted on April 1, 2022 with respect to 16,500 shares of the Issuer's common stock and vests in full on April 1, 2023.

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.